Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 409-411

  Imashimizu, Kohta ^a   Shiomi, Kazu ^a   Maeda, Masahiro ^c   Aoki, Naoko ^a,c   Igarashi, Kiyoko ^b   Suzuki, Fumio ^b   Koizumi, Mitsuru ^d   Suzuki, Kenji ^a   Hino, Okio ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b Environmental Carcinogenesis Research Center   (Japan)

^c Immuno Biological Laboratories Co Ltd   (Japan)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

ELISA; Mesothelin; Mesothelioma; Screening

Indexed keywords

ASBESTOS; MESOTHELIN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTRUCTION WORK; CYTOLOGY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; THORAX RADIOGRAPHY;

EID: 79953279813     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.225     Document Type: Article

References (8)

1. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW and De Klerk N: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.
2. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A and Hino O: Novel ELISA system for detection of NERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97: 928-932, 2006.
3. Shiomi K, Hagiwara Y, Sonoue K, et al: Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 14: 1431-1437, 2008.
4. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham M and Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin for targeted therapy of mesothelin-expressing mesotheliomas, ovarian and pancreatic cancer. J Clin Oncol 25: 3553, 2007.
5. Hassan R, Ebel W, Routhier E, et al: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7: 20-29, 2007.
6. Hassan R and Ho M: Mesothelin-targeted cancer immunotherapy. Eur J cancer 44: 46-53, 2008.
7. Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama M, Watanabe S and Hino O: Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci 101: 969-974, 2010.
8. Yoshida C, Sogawa C, Tsuji A, Sudo H, Sugyo A, Uehara T, Hino O, Yoshii Y, Fujibayashi Y, Fukumura T, Koizumi M, Arano Y and Saga T: Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/ mesothelin in mesothelioma mouse model. Nucl Med Commun 31: 380-388, 2010.